Christophe Weber (Miho Takahashi/The Yomiuri Shimbun via AP Images)
December 22, 2021 10:19 AM EST
FDA+

Months af­ter miss­ing its PDU­FA date, FDA slaps down Takeda's old Shire drug for eosinophilic esophagi­tis

Nicole DeFeudis

Editor

Take­da CEO Christophe We­ber thought he had a win in the bag for TAK-721 — one of the ex­per­i­men­tal drugs spot­light­ed in the com­pa­ny’s

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

Director Oligonucleotide R&D

Bachem

Bubendorf, BL, Switzerland

TRENDING NOW

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

FDA lifts hold on En­trada's Duchenne drug af­ter two years

Sanofi, Te­va bol­ster case for IBD drug with Phase 2 da­ta, de­spite po­ten­tial com­pe­ti­tion

sponsored

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

A service from the Financial Times